Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Zydus Lifesciences and its US subsidiary have finalized a patent dispute settlement with Astellas Pharma concerning the US rights to Mirabegron, marketed as Myrbetriq by Astellas. Under the terms, Zydus will pay $120 million upfront plus a per-unit royalty on generic sales through September 2027, allowing uninterrupte…
Share This Article
Ready-to-post copy includes the article link.
Zydus Lifesciences Reaches $120 Million Patent Settlement with Astellas Over Mirabegron in US Market Zydus Lifesciences and its US subsidiary have finalized a patent dispute settlement with Astellas Pharma concerning the US rights to Mirabegron, marketed as Myrbetriq by Astellas. Under the terms, Zydus will pay $120 mi... Read the full IIPLA article: https://iipla.org/news/zydus-lifesciences-reaches-120-million-patent-settlement-with-astellas-over-mirabegron-in-us-market